Jump to content

Cryoimmunotherapy

From Wikipedia, the free encyclopedia
(Redirected from Cryoimmunology)

Cryoimmunotherapy, also referred to as cryoimmunology, is an oncological treatment for various cancers that combines cryoablation of tumor with immunotherapy treatment.[1] In-vivo cryoablation of a tumor, alone, can induce an immunostimulatory, systemic anti-tumor response, resulting in a cancer vaccine—the abscopal effect.[2] Thus, cryoablation of tumors is a way of achieving autologous, in-vivo tumor lysate vaccine and treat metastatic disease.[3][4] However, cryoablation alone may produce an insufficient immune response, depending on various factors, such as high freeze rate.[5] Combining cryotherapy with immunotherapy enhances the immunostimulating response and has synergistic effects for cancer treatment.[6]

Although, cryoblation and immunotherapy has been used successfully in oncological clinical practice for over 100 years,[7][8] and can treat metastatic disease with curative intent, it has been ignored in modern practice. Only recently has cryoimmunotherapy been resurrected to become the gold standard in cancer treatment of all stages of disease.[9]

History

[edit]

Immunological effects resulting from the cryoablation of tumors was first observed in the 1960s.[10][11] Since the 1960s, Tanaka treated metastatic breast cancer patients with cryotherapy and reported cryoimmunological reaction resulting from cryotherapy.[12][13] In the 1970s, systemic immunological response from local cryoablation of prostate cancer was also clinically observed.[14][15][16] In the 1980s, Tanaka, of Japan, continued to advance the clinical practice of cryoimmunology with combination treatments including: cryochemotherapy and cryoimmunotherapy.[17] In 1997, Russian scientists confirmed the efficacy of cryoimmunotherapy in inhibiting metastases in advanced cancer.[18] In 2000s, China, following closely with the exciting developments, enthusiastically embraced cryoablation treatment for cancer and has been leading the practice ever since with cryoimmunotherapy treatments available for cancer patients in numerous hospitals and medical clinics throughout China.[19][20] In the 2010s, American researchers and medical professionals, started to explore cryoimmunotherapy for systemic treatment of cancer.[21]

Mechanisms of actions

[edit]

Cryoablation of tumor induces necrosis of tumor cells. The immunotherapeutic effect of cryoablation of tumor is the result of the release of intracellular tumor antigens from within the necrotized tumor cells. The released tumor antigens help activate anti-tumor T cells, which destroy remaining malignant cells. Thus, cryoablation of tumor elicits a systemic anti-tumor immunologic response.[22][23][24]

The resulting immunostimulation from cryoablation may not be sufficient to induce sustained, systemic regression of metastases, and can be synergised with the combination of immunotherapy treatment and vaccine adjuvants.[25]

Various adjuvant immunotherapy and chemotherapy treatments can be combined with cryoablation to sustain systemic anti-tumor response with regression of metastases, including:

  • Injection of immunomodulating drugs (i.e.: therapeutic antibodies) and vaccine adjuvants (saponins) directly into the cryoablated, necrotized tumor lysate, immediately after cryoablation
  • Administration of autologous immune enhancement therapy, including: dendritic cell therapy, CIK cell therapy

See also

[edit]

References

[edit]
  1. ^ Sidana Abhinav (2014). "Cancer immunotherapy using tumor cryoablation". Immunotherapy. 6 (1): 85–93. doi:10.2217/imt.13.151. PMID 24341887.
  2. ^ Tarkowski R, Rzaca M (2005). "Immunologic response to cryoablation of breast cancer". Gland Surg. 3 (2): 88–93. doi:10.3978/j.issn.2227-684X.2014.03.04. PMC 4115762. PMID 25083502.
  3. ^ Conway, Sarah (2016-03-02). "Harnessing ultrasound-guided cryoablation for breast cancer". Applied Radiology. Retrieved 2024-08-06.
  4. ^ Tsuchiya, Hiroyuki; Namiki, Mikio; Mizokami, Atsushi; Tanzawa, Yoshikazu; Takeuchi, Akihiko; Hayashi, Katsuhiro; Shirai, Toshiharu; Nishida, Hideji (2011). "Cryotreatment against Metastatic Renal Cell Bone Tumour Reduced Multiple Lung Metastases". Anticancer Research. 31 (9): 2927–2930. PMID 21868540.
  5. ^ Sabel MS, Su G, Griffith KA, Chang AE (2010). "Rate of freeze alters the immunologic response after cryoablation of breast cancer". Annals of Surgical Oncology. 17 (4): 1187–1193. doi:10.1245/s10434-009-0846-1. PMID 20033323. S2CID 30048369.
  6. ^ Haen, SP; Pereira, PL; Salih, HR; Rammensee, HG; Gouttefangeas, C (2011). "More Than Just Tumor Destruction: Immunomodulation by Thermal Ablation of Cancer". Clin Dev Immunol. 2011: 1–19. doi:10.1155/2011/160250. PMC 3254009. PMID 22242035.
  7. ^ History of Cryosurgery. 2008.
  8. ^ McCarthy EF (2006). "The Toxins of William B. Coley and the Treatment of Cancer". Iowa Orthop J. 26: 154–8. PMC 1888599. PMID 16789469.
  9. ^ "About Cryotherapy".
  10. ^ Mehta Amol (2016). "Thermal Ablative Therapies and Immune Checkpoint Modulation: Can Locoregional Approaches Effect a Systemic Response". Gastroenterol Res Pract. 2016: 1–11. doi:10.1155/2016/9251375. PMC 4802022. PMID 27051417.
  11. ^ Yantorno C, Soanes WA, Gonder MJ, Shulman S (1967). "Studies in cryo-immunology". Immunology. 12 (4): 395–410. PMC 1409203. PMID 4960713.
  12. ^ Tanaka (1982). "Immunological aspects of cryosurgery in general surgery". Cryobiology. 19 (3): 247–62. doi:10.1016/0011-2240(82)90151-1. PMID 7105777.
  13. ^ Richard J. Ablin (1998). "The Use of Cryosurgery for Breast Cancer". Arch Surg. 133 (1): 106. doi:10.1001/archsurg.133.1.106. PMID 9438770.
  14. ^ Soanes WA, Ablin RJ, Gonder MJ (1970). "Remission of metastatic lesions following cryosurgery in prostatic cancer: immunologic considerations". J Urol. 104 (1): 154–9. doi:10.1016/s0022-5347(17)61690-2. PMID 4987666.
  15. ^ Ablin, Richard J.; Fontana, Gabriele (1979). "Cryoimmunotherapy: Continuing Studies toward Determining a Rational Approach for Assessing the Candidacy of the Prostatic Cancer Patient for Cryoimmunotherapy and Postoperative Responsiveness". Eur Surg Res. 11 (4): 223–233. doi:10.1159/000128070. PMID 527611.
  16. ^ R. J. Ablin; et al. (1971). "Prospects for Cryo-Immunotherapy in Cases of Metastasizing Carcinoma of the Prostate". Cryobiology. 8 (3): 271–279. doi:10.1016/0011-2240(71)90050-2. PMID 5570410.
  17. ^ Tanaka (1985). "Cryotherapy" (in general surgery and related areas).". Gan No Rinsho. 31 (6 Suppl): 712–20. PMID 3897620.
  18. ^ Vladimir Mouraviev, M.D (1997). "THE GUIDED CRYOIMMUNOTHERAPY IN THE ADVANCED PROSTATE CANCER".
  19. ^ "China: New Chair of the International Society of Cryosurgery (ISC)". 2015. Archived from the original on 2016-10-20. Retrieved 2016-10-20.
  20. ^ "Minimally Invasive Breast Cancer Cryotherapy Largely Ignored in U.S., Says Advocate and 13-Year Survivor". 2016. Archived from the original on 2016-10-20. Retrieved 2016-10-20.
  21. ^ Veenstra JJ, Gibson HM, Freytag S, Littrup PJ, Wei WZ (2015). "In situ immunization via non-surgical ablation to prevent local and distant tumor recurrence". Oncoimmunology. 4 (3): e989762. doi:10.4161/2162402X.2014.989762. PMC 4404795. PMID 25949901.
  22. ^ Xu, Lisa X.; Liu, Ping; He, Kun; Zhang, Aili; Zhang, Yan; Zhu, Jun (2015). "Cryo-thermal therapy elicits potent anti-tumor immunity". Scientific Reports. 6: 27136. doi:10.1038/srep27136. PMC 4891716. PMID 27256519.
  23. ^ Cryosurgery initiates inflammation and leaves tumor-specific antigens intact, which may induce an anti-tumor immune response.Sabel (2005). "Immunologic response to cryoablation of breast cancer". Gland Surg. 3 (2): 88–93. doi:10.3978/j.issn.2227-684X.2014.03.04. PMC 4115762. PMID 25083502.
  24. ^ Machlenkin, A.; Goldberger, O.; Tirosh, B.; Paz, A.; Volovitz, I.; Bar-Haim, E.; Lee, S. H.; Vadai, E.; Tzehoval, E.; Eisenbach, L. (2005). "Combined Dendritic Cell Cryotherapy of Tumor Induces Systemic Antimetastatic Immunity". Clinical Cancer Research. 11 (13): 4955–4961. doi:10.1158/1078-0432.CCR-04-2422. PMID 16000595.
  25. ^ Mehta Amol (2016). "Thermal Ablative Therapies and Immune Checkpoint Modulation: Can Locoregional Approaches Effect a Systemic Response". Gastroenterol Res Pract. 2016: 1–11. doi:10.1155/2016/9251375. PMC 4802022. PMID 27051417.
[edit]